Korro Bio, Inc.
NASDAQ:KRROBiotechnology
+$1.76 today
- Market cap
- $170.75M
- Beta
- 2.10
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$9.79
Volume 0.16M
Average 0.15M
KRRO Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Korro Bio, Inc.NASDAQ: KRRO
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $7.49M fell 4.4% year over year, ahead of the -15.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 20.9% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.
Context
- Selling, general & admin amounted to 440.5% of revenue in FY2025, down 904.5 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 6 analysts of $7.25M (-74.3%) for the fiscal year ending Dec 2026, a slowdown from the -7.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $7.49M+20.9% QoQ
- Last fiscal yearDec 2025
- $28.16M-7.8% YoY
- LTMMar 2026
- $30.49M-15.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 28.16M USD
- Year-over-year change
- -7.8%
- 4-year CAGR
- -5.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.16M | -7.8% |
| FY2024 | 2024-12-31 | 30.55M | -16.4% |
| FY2023 | 2023-12-31 | 36.54M | +117.5% |
| FY2022 | 2022-12-31 | 16.8M | -51.9% |
| FY2021 | 2021-12-31 | 34.93M | — |
Selling, General & Admin vs competitors
How KRRO compares with its peers on the latest reported figures
- KRRO's LTM Mar 2026 selling, general & admin of $30.49M is the 5th highest of the 11 companies compared; the peer median is $26.93M.
- Its year-over-year change of -15.8% is the 8th highest of 9, against a peer median of +5.4%.
- Selling, general & admin amounts to 793.5% of revenue for KRRO, versus a peer median of 2560.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $99.54M | -33.2% | -27.7% | 46.3% | |
| LTM Mar 2026 | $38.19M | +65.9% | +17.2% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $35.41M | +41.6% | +106.4% | — |
| LTM Mar 2026 | $32.75M | -0.8% | +0.8% | — | |
| LTM Mar 2026 | $30.49M | -15.8% | +18.8% | 793.5% | |
| LTM Mar 2026 | $30.16M | +39.3% | +17.9% | 83769.4% | |
| LTM Mar 2026 | $23.71M | +3.3% | +7.6% | — | |
| LTM Mar 2026 | $23.59M | — | +2.2% | 2560.2% | |
| LTM Mar 2026 | $21.89M | -3.6% | +59.0% | — | |
| LTM Mar 2026 | $19.82M | +7.4% | +14.2% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M | — | +110.6% | — |
| Peer median (excluding KRRO) | $26.93M | +5.4% | +15.7% | 2560.2% | |
Competitors are the stored peer set for KRRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.07M | 0 | 0 | 2.27M | 6.39M |
| Cost of Revenue | 3.84M | 0 | 0 | 0 | 4.28M |
| Gross Profit | 10.23M | 0 | 0 | 2.27M | 2.11M |
| Gross Margin | 72.7% | — | — | 100.0% | 33.0% |
| Research & Development | 59.32M | 42.2M | 57.25M | 63.64M | 65.58M |
| Selling, General & Admin | 34.93M | 16.8M | 36.54M | 30.55M | 28.16M |
| Operating Expenses | 94.26M | 59M | 84.53M | 94.18M | 89.45M |
| Depreciation & Amortization | 3.84M | 2.51M | 3.63M | 3.57M | 4.28M |
| EBITDA | (80.07M) | (56.49M) | (80.9M) | (88.35M) | (83.06M) |
| EBITDA Margin | -569.1% | — | — | -3890.1% | -1299.5% |
| Operating Income | (84.03M) | (59M) | (84.53M) | (91.91M) | (87.34M) |
| Operating Margin | -597.3% | — | — | -4047.1% | -1366.4% |
| Interest Income | 397K | 947K | 0 | 0 | 0 |
| Interest Expense | 764K | 118K | 0 | 0 | 0 |
| Other Income / Expenses | (640K) | 976K | 3.39M | 8.47M | (29.28M) |
| Income Before Tax | (84.67M) | (58.02M) | (81.15M) | (83.44M) | (116.62M) |
| Pre-Tax Margin | -601.9% | — | — | -3674.2% | -1824.5% |
| Income Tax Expense | 15K | 10K | 27K | 141K | 637K |
| Net Income | (84.69M) | (58.03M) | (81.17M) | (83.58M) | (117.26M) |
| Net Margin | -602.0% | — | — | -3680.4% | -1834.5% |
| EPS (Basic) | (4.94) | (227.58) | (53.09) | (9.37) | (12.48) |
| EPS (Diluted) | (4.94) | (227.42) | (53.08) | (9.37) | (12.48) |
| Weighted Avg Shares | 4.45M | 255K | 1.53M | 8.92M | 9.4M |
| Weighted Avg Shares (Diluted) | 4.45M | 255.17K | 1.53M | 8.92M | 9.4M |
Korro Bio, Inc.
NASDAQ:KRRO
Intrinsic Alpha fair value
Locked
Current Price
$12.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.